India, July 30 -- Pulmonx Corporation (LUNG), a medical device company focused on minimally invasive treatments for lung disease, yesterday announced financial results for the second quarter ended June 30, 2026, showing lower revenue compared to the same period last year but improved margins and reduced losses.
Revenue for Q2 2026 was $22.8 million, down 5% from $23.9 million in Q2 2025, reflecting a 6% decline on a constant currency basis. U.S. revenue totaled $14.2 million, a 4% decrease from $14.7 million in the prior year quarter. International revenue came in at $8.6 million, down 6% from $9.1 million in Q2 2025, with a 9% decline on a constant currency basis. Excluding China, international sales grew 12% year-over year, highlighting ...